Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.38 |
| ▸ | TACR2 | P21452 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 7/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 5/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | CDC25A | P30304 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2129610 | 0.84 | NT5E (0.42) | PTPN1PTPN2TACR2BCHECDC25B | |
| SCHEMBL2130169 | 0.83 | BCHE (0.43) | PTPN1PTPN2TACR2BCHECDC25B | |
| SCHEMBL2133682 | 0.82 | PTPN1 (0.43) | PTPN1PTPN2TACR2BCHECDC25B | |
| SCHEMBL2131750 | 0.82 | BCHE (0.41) | PTPN1PTPN2TACR2BCHECDC25B | |
| Hydrochloric Acid SCHEMBL9984358 | 0.79 | PTPN1 (0.41) | PTPN1PTPN2TACR2BCHECDC25B | |
| SCHEMBL9984091 | 0.79 | SLC5A2 (0.45) | PTPN1PTPN2TACR2BCHECDC25B | |
| SCHEMBL2130715 | 0.78 | PTPN1 (0.39) | PTPN1PTPN2TACR2BCHECDC25B | |
| SCHEMBL20643059 | 0.78 | PTPN1 (0.43) | PTPN1PTPN2TACR2BCHECDC25B | |
| SCHEMBL2131297 | 0.78 | PTPN1 (0.43) | PTPN1PTPN2TACR2BCHECDC25B | |
| SCHEMBL9986263 | 0.78 | PTPN1 (0.43) | PTPN1PTPN2TACR2BCHECDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541380-B2 | C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same | GREEN CROSS CORPORATION (KR) | 2013-09-24 | — | — | US | disclosed |
| US-20120101051-A1 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101051-A1 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | SLC5A2, SLC5A1, SLC2A2 | PTPN1 197/4885PTPN2 164/4885TACR2 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.